GoKawiilHistoSonics, a company founded by biomedical engineer Zhen Xu in 2009, is developing a technique called histotripsy to target different types of cancer. Xu has been refining the approach for years in an effort to treat tumor cells without the need for incisions or other potentially invasive procedures.Read Entire Article
This startup wants to destroy cancer tumors using ultrasound instead of surgery
Why This Matters
HistoSonics' development of histotripsy represents a significant advancement in non-invasive cancer treatment, potentially reducing the risks and recovery times associated with traditional surgery. This innovation could transform cancer care by offering more precise and less invasive options for patients. For the tech industry, it highlights the growing role of ultrasound technology and AI-driven precision medicine in healthcare innovation.
Key Takeaways
- Histotripsy offers a non-invasive alternative to traditional cancer surgery.
- The technology could reduce treatment risks and improve patient recovery times.
- This development underscores the increasing integration of advanced ultrasound and AI in medical treatments.
Get alerts for these topics